Drug intelligence / Profile preview

CIN-210

Development stage: Preclinical
Lead developer: CinFina Pharma
Modality: Peptides

Overview

CIN-210 is a novel, first-in-class dual agonist peptide drug under development for the treatment of obesity. It consists of a covalently linked glucagon-like peptide 1 (GLP-1) analog and a peptide YY3-36 (PYY3-36) analog, designed to combine the appetite-suppressant effects of PYY with the metabolic benefits of GLP-1 receptor activation. The dual mechanism aims to provide synergistic weight loss while allowing for lower dosing and improved tolerability compared to single-agent therapies. The drug is being developed by CinFina Pharma, originally in collaboration with Janssen Sciences Ireland UC[1][2][3][9].

Targets

NPY2R (Neuropeptide Y receptor subtype 2)GLP1R (GLP-1R)

Beyond the preview

Go deeper on CIN-210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIN-210.

Explore the full profile